Mycobacterial Infections Potentiated by Biologics
Resource type
Journal Article
Authors/contributors
- Calabrese, Cassandra (Author)
- Winthrop, Kevin L. (Author)
Title
Mycobacterial Infections Potentiated by Biologics
Abstract
Biologic therapies have revolutionized the treatment of immune-mediated inflammatory
diseases but are associated with an increased risk of serious and opportunistic infections,
including tuberculosis and nontuberculous mycobacterial disease. Despite this increased
risk, the overall risk-benefit ratio remains favorable with appropriate screening
and risk assessment. Further population-based studies are needed to establish the
risk of tuberculosis and nontuberculous mycobacterial disease with the new biologics.
This article highlights the incidence and drug-specific risk of tuberculous and nontuberculous
mycobacterial infection in the setting of biologics, screening and prevention, and
treatment of latent tuberculosis in this setting.
Publication
Infectious Disease Clinics
Publisher
Elsevier
Date
2020/06/01
Volume
34
Issue
2
Pages
413-423
Journal Abbr
Infectious Disease Clinics
Accessed
9/1/21, 3:45 PM
PMID
32444014
ISSN
0891-5520, 1557-9824
Language
English
Library Catalog
Citation
Calabrese, C., & Winthrop, K. L. (2020). Mycobacterial Infections Potentiated by Biologics. Infectious Disease Clinics, 34(2), 413–423. https://doi.org/10.1016/j.idc.2020.02.011
HEME-ONC AND CELLULAR THERAPIES
Link to this record